Skip to main content

Timing of Metformin Important in Metformin-Treated Type 2 Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on June 21, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, June 21, 2024 -- Glucose lowering by metformin is greater when given before enteral glucose among patients with type 2 diabetes controlled by metformin monotherapy, according to a study recently published in Diabetologia.

Cong Xie, Ph.D., from the University of Adelaide in Australia, and colleagues studied 16 participants with type 2 diabetes that was relatively well controlled by metformin monotherapy on four separate days. Participants were randomly assigned on each day to receive a bolus infusion of metformin via a nasoduodenal catheter at −60, −30, or 0 minutes (saline at other time points) or saline at all time points (control) followed by an intraduodenal glucose infusion at 0 to 60 minutes.

The researchers identified a treatment-by-time interaction for metformin in terms of reducing plasma glucose levels and increasing plasma glucagon-like peptide 1 (GLP-1) and insulin levels. A greater reduction in plasma glucose levels was seen when metformin was administered at −60 or −30 minutes versus 0 minutes; the increases in plasma GLP-1 were only seen when metformin was administered at −60 or −30 minutes. Metformin enhanced glucose-induced insulin secretion, although it did not influence insulin sensitivity; on the three days when metformin was given, the increases in plasma insulin levels were comparable.

"Metformin is more effective in glucose-lowering when given before, rather than with, enteral glucose, and this is associated with a greater GLP-1 response," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma

WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell...

Dysbiosis in Phylogenetically Diverse Species Associated With Type 2 Diabetes

WEDNESDAY, June 26, 2024 -- The gut microbiome has a potential functional role in the pathogenesis of type 2 diabetes (T2D), according to a study published online June 25 in...

Reported Symptoms Most Sensitive Indicator of Concussion

WEDNESDAY, June 26, 2024 -- Reported symptoms are a more accurate indicator of concussion than the 10-word component Standardized Assessment of Concussion (SAC), according to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.